May 25, 2017

President Signals Intent To Work With Lawmakers On 340B Changes

Inside Health Policy posted an article titled, “President Signals Intent To Work With Lawmakers On 340B Changes.” The article reads as follows;

“The Trump administration wants to work with lawmakers on legislation to improve program integrity in the 340B drug discount program and provide the Health Resources and Services Administration more regulatory authority. HHS’ intentions are laid out in HRSA’s fiscal 2018 budget justification, though the budget includes few details on what such a package would include.

May 23, 2017

The Downward Spiral of the 340B Program

From Warren H. Fong, M.D., President of the Medical Oncology Association of Southern California

As the president of the Medical Oncology Association of Southern California and a practicing oncologist for nearly two decades, I have seen firsthand the negative impact the rapidly escalating abuse of the 340B Drug Pricing Program has had on cancer patients, healthcare costs and society. This growth has occurred without a proportional improvement in services to the poor and underserved — the very patients the program was designed to help. Contrary to former Rep. Henry Waxman’s (D-Calif.) analysis (“A program that works exactly as intended,” May 2), 340B is clearly broken).

May 22, 2017

Price Control Comment

340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation;

SUMMARY: This document reopens the comment period for the June 17, 2015, proposed rule entitled ‘‘340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation.’’ The comment period for the proposed rule, which ended on August 17, 2015, is reopened for 30 days.

Click here to view the comment.

January 3, 2017

340B card helps lower drug costs, helps others

Editor’s Note: The views in the following article are not supported by a number of economists who state that the 340B program increases prices and has little impact on the indigent.

Abilene Recorder Chronicle posted an article titled, “340B card helps lower drug costs, helps others.” The article reads in part as follows;

“For the uninsured and the underinsured, the costs of medical treatment don’t stop with a doctor’s visit and the diagnosis. The next stop, if the funds are available, is the pharmacy, where the cost of treatment can be prohibitive.

December 12, 2016

What a Trump Administration Could Mean for the 340B Drug Program

National Law Review posted an article titled, “What a Trump Administration Could Mean for the 340B Drug Program.” The article reads in part as follows;

“A Republican White House and a Republican-run Congress could bring significant changes to the 340B Drug Pricing Program (“the 340B program”). Many in Washington believe that the new administration and Republicans in Congress will favor the concerns of drug manufacturers over the concerns of providers or health plans. If the price of drugs becomes an issue for the new Congress, it is very likely that drug manufactures will ask Congress to “scale back” or potentially even eliminate the 340B program as the “quid pro quo” for imposing even the most modest forms of drug price regulation.

December 8, 2016

Drugmakers Want Tough Scrutiny of 340B Discount Program

Bloomberg posted an article titled, “Drugmakers Want Tough Scrutiny of 340B Discount Program.” The article reads in part as follows;

“A federal drug discount program for safety-net providers is experiencing rapid growth and deserves tough scrutiny, a group linked to drugmakers said Dec. 6.

The group, AIR 340B, said in a report the federal 340B drug pricing program is expected to reach $23 billion in total drug sales by 2021, up from the estimated program sales for 2016 of $16.1 billion. AIR 340B said the program’s growth has gone unchecked for too long and policymakers should re-examine it to ensure the program is serving its original intent to improve access to drugs for uninsured or vulnerable patients.

September 29, 2016

WELCH CONTINUES PUSH TO REIN IN SKYROCKETING PRESCRIPTION DRUG PRICES

VTDigger.org published an article titled, “Welch Continues Push to Rein in Skyrocketing Prescription Drug Prices.” The article reads in part as follows;

“Rep. Peter Welch (D-VT) today introduced bipartisan legislation with Rep. Morgan Griffith (R-VA) that would address a loophole in the Medicare 340B Drug Pricing Program that is contributing to the rising cost of health care for consumers and threatening access to lifesaving medications. The introduction of this legislation is the latest in Welch’s efforts to fix the broken prescription drug market that has led to unrestrained price increases for consumers and providers.

August 19, 2016

Demonstrating That 340(b) Loses Are Recouped By Increased Prices To The Public

The shortcomings in the 340(b) program have been studied for years.  One reason for the lack of action is that the implications of these shortcomings have not been presented in a manner that demonstrates they affect the consumer. In essence it appears that certain commercial sectors, pharmacies and hospitals, are benefiting at the cost of the pharmaceutical industry.

One purpose of this Interactive Public Docket(IPD) is to subject this public policy issue to an informed analysis with an interactive capability for all interested stakeholders to express their views and submit relevant data. To this end CRE controls all original posts on this page, the home page, but interested stakeholders may post directly on the two forums to the right of this page. Our readers can, however, post comments on CRE articles on the home page but they cannot post a new article.